Gliatilin, 1000 mg/4 ml 4 ml 3 pcs

Gliatin is a neuroprotective.

Pharmacodynamics

It improves nerve impulse transmission in cholinergic neurons; positively influences neuronal membrane plasticity and receptor function. It improves cerebral blood flow, increases metabolic processes in the brain, activates structures of reticular formation of the brain and restores consciousness after traumatic brain injury.

It has a preventive and corrective effect on pathogenetic factors of involutional psycho-organic syndrome such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

On ingestion it is broken down by the action of enzymes into choline and glycerophosphate.

Glyatin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, and on the other hand glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result both have a positive effect on membrane elasticity and on receptor function, which improves synaptic transmission.

Hence, pharmacodynamic studies have shown that Gliatilin acts on synaptic, including cholinergic neurotransmission; neuronal membrane plasticity; and receptor function.

Pharmacokinetics

Absorption when ingested is 88%; easily penetrates through the BBB, accumulates primarily in the brain (brain concentrations reach 45% of blood levels), lungs and liver; 85% is excreted by lungs as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestine.

It does not affect the reproductive cycle and has no teratogenic and mutagenic effects.

Indications

Attention and memory impairment, Stroke sequelae, Alzheimer’s disease, Mental disorders, Aggression and conflict, Headache, Acquired dementia

• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutionary psychoorganic syndromes and consequences of cerebrovascular failure, such as primary and secondary disorders of mnemonic functions, characterized by memory disturbances, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudo-melancholy;
• multiple dementia.

.

Active ingredient

Choline alphoscerate

Composition

Active ingredient:

Choline alphoscerate 1000 mg;

Associates:

water for injection

How to take, the dosage

Adults, in acute conditions: intravenously – in a dose of 1000 mg/day (1 ampoule) or intravenously – 1000-3000 mg/day.

In case of intravenous infusion the content of 1 ampoule (4 ml) is diluted in 50 ml of physiological solution, the infusion rate is 60-80 drops per minute.

The duration of treatment is usually 10 days, but if necessary the treatment can be continued until the positive dynamics appear and the possibility of switching to oral capsules.

Interaction

Drug interactions of the drug Gliatilin have not been established.

Special Instructions

In experimental studies no mutagenic effect of the drug was found.

Impact on the ability to drive and operate machinery Gliatilin does not affect the patient’s ability to engage in potentially dangerous activities.

Contraindications

Hypersensitivity to the ingredients of the drug.

Side effects

Nausea (as a consequence of dopaminergic activation), in which case the drug dose should be reduced. Allergic reactions are possible.

Overdose

Symptoms: nausea.

If this symptom occurs, it is recommended to reduce the dose of the drug.

Pregnancy use

Gliatin is contraindicated in pregnancy, lactation and childhood.

Similarities

Gliatilin, Cerepro, Cereton, Holitilin, Noocholin Rompharma, Choline alphoscerate